Interpretation of the 2023 Recommendation Statement by the U.S. Preventive Services Task Force on the Screening for Hypertensive Disorders of Pregnancy

Hypertensive disorders of pregnancy (HDP) is one of the leading causes of maternal and perinatal mortality worldwide, with increasing incidence and mortality year by year. In 2023, the U.S. Preventive Services Task Force (USPSTF) updated the recommendation statement on screening for hypertensive disorders of pregnancy by evaluating the latest research evidence and analyzing the benefits and harms of screening for HDP. The recommendation, compared with the 2017 version, further affirms the importance of blood pressure measurement in screening for HDP, affirms substantial net benefit, and recommends blood pressure measurement throughout pregnancy to screen for HDP. This article explores and analyzes the key points of this recommendation based on the RIGHT statement for introductions and interpretations of guidelines in Chinese (RIGHT for INT) and its implications for guiding general practitioners in China.